Biolinq lands $58m to advance wearable metabolic health technology

Company targets clinical trial of groundbreaking CGM device that detects blood glucose levels just below the surface of the skin.

Health tech company Biolinq has secured $58 million in new funding to advance its biosensor technology for enhancing metabolic health. The San Diego-based company’s first device is a wearable continuous glucose monitoring patch that measures blood sugar using tiny microneedles, without requiring a separate device to report results.

Utilizing an array of miniature electrochemical sensors to monitor glucose levels from just beneath the skin’s surface, Biolinq’s wearable patch integrates glucose data with a user’s activity levels in a single device. Placed on the upper forearm, the patch features a display that notifies users when glucose levels are within target ranges or if they exceed healthy thresholds.

“Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said Biolinq CEO Rich Yang.

Biolinq’s biosensor platform is designed to offer users a comprehensive view of their metabolic health, merging glucose information with contextual insights into daily activities. The company says that its silicon chip, which houses an array of sensors, has “multi-analyte” capabilities, suggesting that the company will expand beyond glucose sensing into detection of other molecules.

“We have a meaningful opportunity to transform care delivery and enable healthier living by opening up a new frontier in continuous sensing,” said Dan Bradbury, Biolinq’s Chairman.

The new investment will support Biolinq’s efforts to conduct a pivotal clinical trial in the United States this year. This trial will evaluate the efficacy of the proprietary intradermal glucose sensor, paving the way for subsequent FDA submission. Currently, the device is still under investigation and has not received clearance or approval from the FDA or any other regulatory body.

Rich Yang is CEO of Biolinq

The funding round was led by Alpha Wave Ventures, with contributions from Niterra’s corporate venture capital arm in collaboration with Pegasus Tech Ventures and existing investors.

“Companies that disrupt entire industries often don’t originate from a single discipline,” said Rick Gerson, Chairman of Alpha Wave Global. “Biolinq has attracted leading experts in biosensor development, consumer electronics design, proprietary materials science, software engineering and semiconductor manufacturing to build a new category of biowearables.”

Photographs courtesy of Biolinq